Udomkarnjananun Suwasin, Francke Marith I, Dieterich Marjolein, van De Velde Daan, Litjens Nicolle H R, Boer Karin, De Winter Brenda C M, Baan Carla C, Hesselink Dennis A
Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Erasmus MC Transplant Institute, Rotterdam, The Netherlands.
Transplantation. 2023 Feb 1;107(2):382-391. doi: 10.1097/TP.0000000000004287. Epub 2022 Sep 2.
. Transplant recipients may develop rejection despite having adequate tacrolimus whole blood predose concentrations (C 0 ). The intra-immune cellular concentration is potentially a better target than C 0 . However, little is known regarding intracellular tacrolimus concentration in T-lymphocytes and monocytes. We investigated the tacrolimus concentrations in both cell types and their relation with the expression and activity of FK-binding protein (FKBP)-12 and P-glycoprotein (P-gp).
. T-lymphocytes and monocytes were isolated from kidney transplant recipients followed by intracellular tacrolimus concentration measurement. FKBP-12 and P-gp were quantified with Western blot, flow cytometry, and the Rhodamine-123 assay. Interleukin-2 and interferon-γ in T-lymphocytes were measured to quantify the effect of tacrolimus.
. Tacrolimus concentration in T-lymphocytes was lower than in monocytes (15.3 [8.5-33.4] versus 131.0 [73.5-225.1] pg/million cells; P < 0.001). The activity of P-gp (measured by Rhodamine-123 assay) was higher in T-lymphocytes than in monocytes. Flow cytometry demonstrated a higher expression of P-gp (normalized mean fluorescence intensity 1.5 [1.2-1.7] versus 1.2 [1.1-1.4]; P = 0.012) and a lower expression of FKBP-12 (normalized mean fluorescence intensity 1.3 [1.2-1.7] versus 1.5 [1.4-2.0]; P = 0.011) in T-lymphocytes than monocytes. Western blot confirmed these observations. The addition of verapamil, a P-gp inhibitor, resulted in a 2-fold higher intra-T-cell tacrolimus concentration. This was accompanied by a significantly fewer cytokine-producing cells.
. T-lymphocytes have a higher activity of P-gp and lower concentration of the FKBP-12 compared with monocytes. This explains the relatively lower tacrolimus concentration in T-lymphocytes. The addition of verapamil prevents loss of intracellular tacrolimus during the cell isolation process and is required to ensure adequate intracellular concentration measurement.
尽管他克莫司全血给药前浓度(C0)充足,但移植受者仍可能发生排斥反应。免疫细胞内浓度可能是比C0更好的靶点。然而,关于T淋巴细胞和单核细胞内他克莫司浓度的了解甚少。我们研究了这两种细胞类型中的他克莫司浓度及其与FK结合蛋白(FKBP)-12和P-糖蛋白(P-gp)表达及活性的关系。
从肾移植受者中分离出T淋巴细胞和单核细胞,随后测量细胞内他克莫司浓度。用蛋白质免疫印迹法、流式细胞术和罗丹明-123测定法对FKBP-12和P-gp进行定量。测量T淋巴细胞中的白细胞介素-2和干扰素-γ以量化他克莫司的作用。
T淋巴细胞中的他克莫司浓度低于单核细胞(15.3[8.5 - 33.4]对131.0[73.5 - 225.1]pg/百万细胞;P<0.001)。T淋巴细胞中P-gp的活性(通过罗丹明-123测定法测量)高于单核细胞。流式细胞术显示,T淋巴细胞中P-gp的表达较高(标准化平均荧光强度1.5[1.2 - 1.7]对1.2[1.1 - 1.4];P = 0.012),而FKBP-12的表达较低(标准化平均荧光强度1.3[1.2 - 1.7]对1.5[1.4 - 2.0];P = 0.011)。蛋白质免疫印迹法证实了这些观察结果。添加P-gp抑制剂维拉帕米后,T细胞内他克莫司浓度提高了2倍。这伴随着产生细胞因子的细胞显著减少。
与单核细胞相比,T淋巴细胞具有更高的P-gp活性和更低的FKBP-12浓度。这解释了T淋巴细胞中他克莫司浓度相对较低的原因。添加维拉帕米可防止细胞分离过程中细胞内他克莫司的丢失,并且是确保进行充分的细胞内浓度测量所必需的。